A full house presented itself when Inevn2 pitched 8 of their most promising cancer research projects at Oslo Cancer Cluster Incubator June 12.
In total approximately 60 people gathered inside Oslo Cancer Cluster Innovation Park, and among the participants several experienced investors from other cancer projects.
— I’m positively surprised that so many potential and experienced investors found their way here today, commented Ole Kristian Hjelstuen, CEO at Inven2.
The event was the second in line of Inven2’s new pitching strategy, were they open up their projects at an early stage for potential investors and entrepreneurs with the will to transform the research into working companies.
— This shows that pitching is a good way to spread the word on the potential of our portfolio. The event today strengthens my belief that financing for our projects will be easier in the future, said Hjelstuen.
Eight Potential Treatments and Companies
Norway is among the very best when it comes to cancer research. Norwegian research has created top notch companies like Algeta, Nordic Nanovector, Ultimovacs and Zelluna Immunotherapy. Tuesdays pitch proves that many more are on the horizon.
The eight-project presented at OCC Incubator are all exciting innovations that need financial backing and entrepreneurship to commercialize. The common denominator is a focus on modern treatments like immunology or precision medicine that are emerging as a result of what has been labelled “a breakthrough in cancer treatment” in later years.
The projects presented:
- Tankyrase inhibition in cancer therapy
- A new drug against Acute Myeloid Leukaemia (AML)
- Autologous anti-CD20 TCR-engineered T-cell therapy for recurrent Non-Hodgkin’s Lymphoma
- Lymphocyte Booster – Lymphocyte boosting growth medium for Adoptive Cell Therapy
- CD37 CAR for cancer immunotherapy
- IL-15 Immunotherapy – Fusion protein for immunotherapy of solid tumors
- Backscatter: A communication technology enabling colon-cancer screening